Skok, Ochsenhofer et al. present the first reported instance of extraskeletal osteosarcoma with an NTRK fusion. The rapid and sustained response to larotrectinib highlights the potential of precision medicine in managing rare and aggressive tumors, emphasizing the importance of molecular profiling to identify actionable targets.
- Kristijan Skok
- Florian Ochsenhofer
- Bernadette Liegl-Atzwanger
